Clinical Report: Evaluation of Clinical Laboratory Metrics in Adolescents with AD

Overview

The ECZTRA 6 study evaluated clinical laboratory parameters in adolescents with moderate-to-severe atopic dermatitis (AD) receiving tralokinumab for up to 52 weeks. The findings indicate that tralokinumab treatment does not significantly impact laboratory parameters, supporting its use without routine monitoring.

Background

Atopic dermatitis is a prevalent chronic inflammatory skin condition in adolescents, often requiring long-term treatment. Traditional systemic therapies pose safety concerns and necessitate ongoing laboratory monitoring, which can hinder treatment adherence. Tralokinumab, a newer biologic therapy, offers a promising alternative without the need for routine laboratory assessments.

Data Highlights

Nearly all hematology and biochemistry parameters remained within reference ranges, with the exception of eosinophils and immunoglobulin E (IgE). Tralokinumab-treated patients showed a transient increase in eosinophils and a decrease in IgE levels compared to placebo.

Key Findings

• Tralokinumab treatment did not result in clinically significant changes in laboratory parameters in adolescents with moderate-to-severe AD.
• Median eosinophil levels increased transiently in tralokinumab-treated patients by Week 16.
• Median IgE levels decreased in the tralokinumab groups but increased in the placebo group by Week 16.
• Laboratory values were comparable between tralokinumab and placebo groups at baseline and Week 16.
• Routine laboratory monitoring is not required for adolescents receiving tralokinumab.

Clinical Implications

Clinicians can confidently prescribe tralokinumab for adolescents with moderate-to-severe AD without the need for routine laboratory monitoring. This may enhance treatment adherence and reduce the burden of ongoing assessments associated with traditional systemic therapies.

Conclusion

The ECZTRA 6 study supports the safety and efficacy of tralokinumab in adolescents with moderate-to-severe AD, indicating that it does not adversely affect laboratory parameters, thus simplifying management strategies.

References

1. FDA Approves Tralokinumab for Treating Eczema in Adolescents, Medscape, 2023
2. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial, JAMA Dermatology, 2023
3. Clinical Rheumatology — Long-term Use of Subcutaneous Tocilizumab Alone or with Synthetic DMARDs in Rheumatoid Arthritis Patients in Greece: Findings from the EMBRACE Multicenter Observational Study
4. Drugs - Real World Outcomes — Evaluation of Topical Tacrolimus and Pimecrolimus Utilization Across Four European Nations: A Multicenter Database Analysis
5. Clinical Rheumatology — Efficacy, safety, and pharmacokinetic profile of adalimumab in young children aged 2 to 4 with polyarticular juvenile idiopathic arthritis
6. Clinical Rheumatology — Assessment of the safety and effectiveness of tocilizumab in Chinese individuals with systemic juvenile idiopathic arthritis: results from a multicenter phase IV study
7. FDA Approves Tralokinumab for Treating Eczema in Adolescents
8. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial | Trials | JAMA Dermatology | JAMA Network
9. 2025 Update of AAD Atopic Dermatitis Clinical Guidelines - Guideline Summary - Guideline Central